BioBlast Pharma's (ORPN) Cabaletta Fast Track Designation Viewed as Incremental Positive by Roth Capital; 'Buy' Rating Affirmed
Tweet Send to a Friend
Roth Capital affirmed BioBlast Pharma Ltd. (Nasdaq: ORPN) with a Buy rating and $18 price target after the company announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
